Home ›
Lung Cancer Trials ›
NCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Trial Details
NCT ID NCT07863167
Phase PHASE2
Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status RECRUITING
Cancer Type Lung Cancer
Interventions adebrelimab + SHR-A2009 paclitaxel or pemetrexed combined with carboplatin +adebrelimab adebrelimab adebeliizumab + SHR-A2009 adebeliizumab + platinum-containing double chemotherapy almonertinib combined with SHR-A2009
Locations (sample) Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ; At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can. The ECOG score was 0 or 1. Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →